A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma

Robert T O'Donnell, Gerald L Denardo, David L. Kukis, Kathleen R. Lamborn, Sui Shen, Aina Yuan, Desiree S. Goldstein, Catherine E. Carr, Gary R. Mirick, Sally J. DeNardo

Research output: Contribution to journalArticle

84 Scopus citations


Encouraged by the results of 131I-Lym-1 therapy trials for patients with B-cell non-Hodgkin's lymphoma (NHL), this phase I/II clinical trial of 67Cu-2IT-BAT-Lym-1 was conducted in an effort to further improve the therapeutic index of Lym-1-based radioimmunotherapy. Lym-1 is a mouse monoclonal antibody that preferentially targets malignant lymphocytes. 67Cu has beta emissions comparable to those of 131I but has gamma emissions more favorable for imaging. The macrocyclic chelating agent 1,4,7,11- tetraazacyclotetradecane-N,N',N',N''-tetraacetic acid binds 67Cu tightly to form a stable radioimmunoconjugate in vivo. Methods: All 12 patients had stage III or IV NHL that had not responded to standard therapy; 11 had intermediate- or high-grade NHL. At 4-wk intervals, patients received up to four doses of 67Cu-2IT-BAT-Lym-1, 0.93 or 1.85-2.22 GBq/m2 (25 or 50-60 mCi/m2), with the lower dose used when NHL was detected in the bone marrow. Results: 67Cu-2IT-BAT-Lym-1 provided good imaging of NHL and favorable radiation dosimetry. The mean radiation ratios of tumor to body and tumor to marrow were 28:1 and 15:1, respectively. Tumor-to-lung, -kidney and -liver radiation dose ratios were 7.4:1, 5.3:1 and 2.6:1, respectively. This 67Gu- 2IT-BAT-Lym-1 trial for patients with chemotherapy-resistant NHL had a response rate of 58% (7/12). No significant nonhematologic toxicity was observed. Hematologic toxicity, especially thrombocytopenia, was dose limiting. Conclusion: 67Cu remains an option for future clinical trials. This study established 67Cu-2IT-BAT-Lym-1 as a safe, effective treatment for patients with NHL.

Original languageEnglish (US)
Pages (from-to)2014-2020
Number of pages7
JournalJournal of Nuclear Medicine
Issue number12
StatePublished - Dec 1999


  • Cu
  • Antibody
  • Immunotherapy
  • Lymphoma
  • Radiotherapy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'A clinical trial of radioimmunotherapy with <sup>67</sup>Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this

    O'Donnell, R. T., Denardo, G. L., Kukis, D. L., Lamborn, K. R., Shen, S., Yuan, A., Goldstein, D. S., Carr, C. E., Mirick, G. R., & DeNardo, S. J. (1999). A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma. Journal of Nuclear Medicine, 40(12), 2014-2020.